Home/Filings/8-K/0001493152-26-002057
8-K//Current report

Aspire Biopharma Holdings, Inc. 8-K

Accession 0001493152-26-002057

$ASBPCIK 0001847345operating

Filed

Jan 12, 7:00 PM ET

Accepted

Jan 13, 4:30 PM ET

Size

252.8 KB

Accession

0001493152-26-002057

Research Summary

AI-generated summary of this filing

Updated

Aspire Biopharma Reports Director Resignation — Surendra Ajjarapu

What Happened Aspire Biopharma Holdings, Inc. (ASBP) filed a Form 8-K (Item 5.02) reporting that Director Surendra Ajjarapu notified the Board on January 7, 2026 that he would step down from his role as a director effective immediately. The filing states his decision was not due to any disagreement with the company, the Board, or management.

Key Details

  • Filing type: Form 8-K (Item 5.02), filed January 13, 2026.
  • Resignation notice date and effective date: January 7, 2026 — effective immediately.
  • Reason: Company states resignation was not due to any disagreement with the company, the Board, or management.
  • Exhibit: Cover Page Interactive Data File (Inline XBRL) included in the filing.

Why It Matters A director resignation is a governance event investors watch because it can affect board composition and oversight. This filing provides the key facts (resignation date and that it was not due to any dispute), but does not disclose a replacement or changes to board committees. Investors should monitor future filings or company announcements for any appointment of a new director or related governance updates.